Last reviewed 2026-03-25 · How we verify

Myelodysplastic Syndromes (MDS)

Approved treatments

No approved treatments tracked yet.

Clinical guidelines

• FDA label — 1L|2L|3L+
  Lenalidomide is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
• FDA label — 3L+
  Lenalidomide is indicated for the treatment of adult patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Myelodysplastic Syndromes (MDS) treatment landscape brief
• Myelodysplastic Syndromes (MDS) treatment updates RSS